Abstract: Malignant pleural mesothelioma (MPM) represents the uncommon cancer originating from pleural mesothelial cells, which is associated with dismal prognostic outcome. According to CheckMate-743 results, nivolumab plus ipilimumab has been approved to treat the unresectable MPM in treatment-naive patients as a first-line therapy by the FDA in October 2020. Immunotherapy is expected to be the best choice for MPM treatment. In the following article, the past treatment plan and the progress of immunotherapy for MPM will be reviewed.

Keywords: malignant pleural mesothelioma, immunotherapy, progression, ipilimumab, nivolumab


中文翻译：

---

恶性胸膜间皮瘤免疫治疗进展

摘要：恶性胸膜间皮瘤（MPM）是一种起源于胸膜间皮细胞的罕见癌症，预后不良。根据CheckMate-743结果，2020年10月，FDA已批准nivolumab加ipilimumab作为一线疗法用于治疗初治患者不可切除的MPM，免疫疗法有望成为MPM治疗的最佳选择。在下一篇文章中，将回顾MPM过去的治疗方案和免疫治疗的进展。

关键词：恶性胸膜间皮瘤，免疫治疗，进展，易普利姆玛，纳武单抗